See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
autoimmune disease. It is a subgroup of the idiopathic (unknown cause) inflammatory muscle diseases (myopathies) and is characterized by myositis, interstitial lung disease, arthritis, Raynaud's phenomenon and the finding of autoantibodies to “aminoacyl transfer RNA synthetases” (anti-ARS) in a blood exam. The exact cause is not known. The diagnosis is based on the clinical features and is confirmed in the presence of positive serologic testing for anti-ARS antibodies (anti-Jo-1, anti-PL-12, anti-PL-7, anti-OJ; anti-KS). The treatment is done with oral corticosteroids (prednisone) and other immunosuppressive agents.Antisynthetase syndrome is a chronic
Last updated: 4/28/2015
- Tzioufas AG. Orphanet. November 2001; http://www.orpha.net/data/patho/Pro/en/Antisynthetase-FRenPro8611.pdf. Accessed 5/12/2008.
- Antisynthetase syndrome. Orphanet. May, 2014; http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=8611. Accessed 4/28/2015.
- Solomon J, Swigris JJ &, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. February, 2011; 37(1):100–109. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676869/. Accessed 4/28/2015.
- More information on arthritis can be found by visiting MedlinePlus, the National Library of Medicine Web site designed to help you research your health questions.
- MedlinePlus, the National Library of Medicine Web site designed to help you research your health questions, provides general information on myositis. Click on the link to view this information.
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) provides comprehensive information on Raynaud's phenomenon. To read this information, click on the link.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Antisynthetase syndrome. Click on the link to view a sample search on this topic.